Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity.

Jia Q, Ng Q, Chin W, Meng T, Chow VTK, Wang CI, Kwang J, He F.

Sci Rep. 2017 Apr 19;7:46402. doi: 10.1038/srep46402.

2.

A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein.

Kiener TK, Jia Q, Meng T, Chow VT, Kwang J.

PLoS Negl Trop Dis. 2014 May 29;8(5):e2895. doi: 10.1371/journal.pntd.0002895. eCollection 2014.

3.

A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.

Jiang L, Fan R, Sun S, Fan P, Su W, Zhou Y, Gao F, Xu F, Kong W, Jiang C.

Vaccine. 2015 Nov 27;33(48):6596-603. doi: 10.1016/j.vaccine.2015.10.104. Epub 2015 Oct 31.

PMID:
26529072
4.

Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein.

Kiener TK, Jia Q, Lim XF, He F, Meng T, Chow VT, Kwang J.

Virol J. 2012 Feb 24;9:55. doi: 10.1186/1743-422X-9-55.

5.

Identification and characterization of a cross-neutralization epitope of Enterovirus 71.

Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P.

Vaccine. 2011 Jun 10;29(26):4362-72. doi: 10.1016/j.vaccine.2011.04.010. Epub 2011 Apr 16.

PMID:
21501643
6.

Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection.

Lim XF, Jia Q, Khong WX, Yan B, Premanand B, Alonso S, Chow VT, Kwang J.

PLoS One. 2012;7(1):e29751. doi: 10.1371/journal.pone.0029751. Epub 2012 Jan 18.

7.

Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps.

Ku Z, Ye X, Huang X, Cai Y, Liu Q, Li Y, Su Z, Huang Z.

PLoS One. 2013;8(2):e57601. doi: 10.1371/journal.pone.0057601. Epub 2013 Feb 22.

8.

Generation and characterization of a protective mouse monoclonal antibody against human enterovirus 71.

Deng YQ, Ma J, Xu LJ, Li YX, Zhao H, Han JF, Tao J, Li XF, Zhu SY, Qin ED, Qin CF.

Appl Microbiol Biotechnol. 2015 Sep;99(18):7663-71. doi: 10.1007/s00253-015-6652-8. Epub 2015 May 13.

PMID:
25967656
10.

Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms.

Ye X, Ku Z, Liu Q, Wang X, Shi J, Zhang Y, Kong L, Cong Y, Huang Z.

J Virol. 2014 Jan;88(1):72-81. doi: 10.1128/JVI.01848-13. Epub 2013 Oct 16.

11.

Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop.

Xu L, He D, Li Z, Zheng J, Yang L, Yu M, Yu H, Chen Y, Que Y, Shih JW, Liu G, Zhang J, Zhao Q, Cheng T, Xia N.

Theranostics. 2014 Feb 18;4(5):498-513. doi: 10.7150/thno.7457. eCollection 2014.

12.

Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide.

Foo DG, Alonso S, Chow VT, Poh CL.

Microbes Infect. 2007 Sep;9(11):1299-306. Epub 2007 Jun 10.

PMID:
17890123
13.

Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.

Tian X, Su X, Li X, Li H, Li T, Zhou Z, Zhong T, Zhou R.

PLoS One. 2012;7(7):e41381. doi: 10.1371/journal.pone.0041381. Epub 2012 Jul 27. Erratum in: PLoS One. 2012;7(10). doi:10.1371/annotation/2da932d4-8654-45c8-bf83-7b3b09dbc146.

14.

Monoclonal antibodies for diagnosis of enterovirus 71.

Xu L, Huang KJ, Ho TS, Liu CC, Lee YR, Lin CY, Shiuan D, Jiang XH.

Monoclon Antib Immunodiagn Immunother. 2013 Dec;32(6):386-94. doi: 10.1089/mab.2013.0033.

PMID:
24328741
15.

Production of EV71 vaccine candidates.

Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, Liu SJ, Chow YH, Su IJ, Klein M.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1775-83. doi: 10.4161/hv.21739. Epub 2012 Sep 19. Review.

16.

Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses.

Zhao M, Bai Y, Liu W, Xiao X, Huang Y, Cen S, Chan PK, Sun X, Sheng W, Zeng Y.

BMC Microbiol. 2013 Dec 10;13:287. doi: 10.1186/1471-2180-13-287.

17.

A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice.

Ku Z, Liu Q, Ye X, Cai Y, Wang X, Shi J, Li D, Jin X, An W, Huang Z.

Vaccine. 2014 Jul 23;32(34):4296-303. doi: 10.1016/j.vaccine.2014.06.025. Epub 2014 Jun 17.

PMID:
24950363
18.

Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides.

Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL.

Virus Res. 2007 Apr;125(1):61-8. Epub 2007 Jan 12.

PMID:
17222936
19.

An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys.

Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, Iwasaki T, Sata T, Wakita T, Shimizu H.

J Virol. 2007 Sep;81(17):9386-95. Epub 2007 Jun 13.

20.

A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.

Cai Y, Ku Z, Liu Q, Leng Q, Huang Z.

Vaccine. 2014 May 1;32(21):2406-12. doi: 10.1016/j.vaccine.2014.03.012. Epub 2014 Mar 18.

PMID:
24657161

Supplemental Content

Support Center